Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
Lung Cancer|Chemotherapy-Induced Thrombocytopenia|Non-Small Cell Lung Cancer|Cancer|Lung Neoplasms|Oncology|Solid Tumors|Thrombocytopenia
BIOLOGICAL: Romiplostim|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Cisplatin
Number of Participants With Adverse Events, This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study., 4 months
Duration of Grade 3 or 4 Thrombocytopenia, The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \<50 x 10\^9/L) experienced during the first on study chemotherapy cycle by treatment group., 3 weeks|Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle., The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \< 50 x 10\^9/L, but â‰¥ 25 x 10\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \< 25 x 10\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia., 3 weeks|Number of Participants With Platelet Transfusions, Number of participants who were administered platelet transfusions during first on study treatment cycle., 3 weeks|Platelet Count on Day 22, Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group, Day 22|Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle, Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle., 8 days
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.